{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:32:14Z","timestamp":1761863534754,"version":"3.40.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.clinthera.2016.02.016","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T18:05:24Z","timestamp":1458065124000},"page":"961-973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct01813435","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02270242","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-6629","authenticated-orcid":false,"given":"Ioannis","family":"Mastoris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Maria Mathias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.02.016_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.76.1.125","article-title":"Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty","volume":"76","author":"Barnathan","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJM198806303182603","article-title":"Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty","volume":"318","author":"Schwartz","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM199408253310802","article-title":"A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators","volume":"331","author":"Fischman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group","volume":"331","author":"Serruys","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.CIR.89.3.1126","article-title":"Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group","volume":"89","author":"Sutton","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib7","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.02.016_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib9","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(01)06585-0","article-title":"Acute coronary syndrome without ST elevation: implementation of new guidelines","volume":"358","author":"Hamm","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib14","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib15","first-page":"2510","article-title":"3 vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.02.016_bib16","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second generation drug-eluting stents implantation followed by six versus twelve-month - dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib18","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib19","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib20","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ahj.2010.07.034","volume":"160","author":"Valgimigli","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2016.02.016_bib22","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2016.02.016_bib23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents","volume":"368","author":"Stefanini","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib24","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib25","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2016.02.016_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib28","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2010.07.038","volume":"160","author":"Mauri","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2016.02.016_bib29","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib30","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","article-title":"Extended duration dual antiplatelet therapy and mortality: .a systematic review and meta-analysis","volume":"385","author":"Elmariah","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib32","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1161\/CIR.0b013e31823ba622","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib33","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2016.02.016_bib34","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib35","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2016.02.016_bib36","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib38","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/CIRCULATIONAHA.114.008643","article-title":"Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry","volume":"129","author":"Steinberg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib39","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.02.016_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2016.02.016_bib41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2016.02.016_bib42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jacc.2015.06.1339","article-title":"Long-term outcomes in patients with diabetes mellitus related to prolonging clopidogrel more than 12 months after coronary stenting","volume":"66","author":"Thukkani","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib43","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2016.02.016_bib44","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jacc.2011.06.049","article-title":"Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials","volume":"58","author":"Baber","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib46","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.02.016_bib47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","article-title":"Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment","volume":"116","author":"Airoldi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.016_bib48","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry","volume":"53","author":"van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib49","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMe1413297","article-title":"Dual antiplatelet therapy after drug-eluting stents--how long to treat?","volume":"371","author":"Colombo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib50","unstructured":"Yeh RW. Individualizing treatment duration of dual antiplatelet therapy after percutaneous coronary intervention: an analysis from the DAPT study. Presented at: American Heart Association Scientific Sessions; November 10 2015, Orlando, FL."},{"key":"10.1016\/j.clinthera.2016.02.016_bib51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.02.016_bib52","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jacc.2005.03.074","article-title":"Atherothrombosis and high-risk plaque: part I: evolving concepts","volume":"46","author":"Fuster","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib53","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2010.07.016","article-title":"Stent thrombosis","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib54","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jcin.2014.04.017","article-title":"Correlates and outcomes of late and very\u00a0late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event\u00a0Registry of Thrombosis)","volume":"7","author":"Waksman","year":"2014","journal-title":"J Am Coll Cardiol Interv"},{"key":"10.1016\/j.clinthera.2016.02.016_bib55","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.02.016_bib56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.02.016_bib57","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"Mehran","year":"2011","journal-title":"J Am Coll Cardiol Interv"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816300765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816300765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T05:21:24Z","timestamp":1536902484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816300765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0149291816300765"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.02.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}